Myriad Genetics (MYGN) says that a study published in the British Journal of Cancer has...


Myriad Genetics (MYGN) says that a study published in the British Journal of Cancer has demonstrated, with highly statistically significant results, the ability of it's Homologous Recombination Deficiency Assay to detect loss of DNA repair in ovarian tumors.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs